Barclays Initiates Coverage of Axogen with Overweight Rating
Fintel reports that on October 7, 2026, Barclays initiated coverage of Axogen (NASDAQCM:AXGN) (LSE:0HKD) with a Overweight recommendation. AxoGen, Inc., based in the United States, operates primarily in the healthcare sector, focusing on the development and commercialization of technologies for peripheral nerve regeneration and repair. The company is a pioneer in offering an extensive portfolio of products such as Avance® Nerve Graft, which leverages human tissue for bridging nerve discontinuities, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector for nerve protection and reconstruction, and AxoTouch®, an electrodiagnostic device for nerve function assessment. These innovative solutions are geared towards numerous surgical nerve repair needs, catering to both trauma and surgical reconstruction markets.
Prior to this coverage initiation, other analyst firms updated their views on the stock. On October 1, 2026, Truist Securities maintained its Buy rating. On September 25, 2026, Raymond James maintained its Outperform rating.
The latest close for the stock was $36.31 on October 6, 2026, which was also the pre-action close. This price represents a one-week price change of -14.44% from a baseline close of $42.44 on September 29, 2026. Over a one-month period, the price change was -24.79% from a baseline close of $48.28 on September 4, 2026.
As of October 3, 2026, the current consensus target mean was $54.77, and the median was $55.08. This mean target represents an implied change of +50.85%. The prior consensus target mean was $54.98 as of September 15, 2026, which reflects a consensus target revision of -0.37%.
Axogen last reported earnings on July 29, 2026, with an actual EPS of 0.12 compared to an estimate of 0.1239, representing an EPS surprise of -3.15%. The actual revenue was $69,731,000.00, compared to the estimate of $68,440,408.00. The company's upcoming earnings date is scheduled for October 27, 2026.
For the current recommendation period of September 1, 2026, there were 16 total recommendations, consisting of 4 strong buy, 11 buy, 1 hold, 0 sell, and 0 strong sell ratings. This breakdown represents 93.8% positive, 6.3% hold, and 0.0% negative recommendations. In the prior recommendation period of August 1, 2026, there were 15 total recommendations, including 4 strong buy, 10 buy, 1 hold, 0 sell, and 0 strong sell ratings, representing 93.3% positive, 6.7% hold, and 0.0% negative recommendations.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| October 7, 2026 | Barclays | Overweight | initiated coverage | |
| October 1, 2026 | Truist Securities | Buy | Buy | maintained |
| September 25, 2026 | Raymond James | Outperform | Outperform | maintained |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.